Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrzej Rynkiewicz

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
European Heart Journal|April 28, 2025
ApoB-containing lipoproteins: count, type, size, and risk of coronary artery diseaseJakub Morze, Giorgio E M Melloni, Clemens Wittenbecher, et al.
Kardiologia Polska|April 22, 2016
[Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement]Barbara Cybulska, Zbigniew Gaciong, Piotr Hoffman, et al.
The Cochrane Database of Systematic Reviews|October 25, 2021
Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysisTakayoshi Kanie, Atsushi Mizuno, Yoshimitsu Takaoka, et al.
The Journal of Invasive Cardiology|November 5, 2013
Major adverse cardiovascular events after drug-eluting stent implantation in patients with single chronic total occlusion: a single-center registryNatasza Gilis-Siek, Marcin Fijalkowski, Milosz Jaguszewski, et al.
Life (Basel, Switzerland)|November 7, 2020
Monitoring the Effects of Hypolipidemic Treatment in Children with Familial Hypercholesterolemia in PolandMatylda Hennig, Agnieszka Brandt-Varma, Anna Wołoszyn-Durkiewicz, et al.
Journal of Clinical Lipidology|June 4, 2013
Management of familial heterozygous hypercholesterolemia: Position Paper of the Polish Lipid Expert ForumAndrzej Rynkiewicz, Barbara Cybulska, Maciej Banach, et al.
Cardiovascular Diabetology|November 23, 2018
Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier?Guntram Schernthaner, Chaim Lotan, Elina Baltadzhieva-Trendafilova, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|January 21, 2015
Successful versus unsuccessful antegrade recanalization of single chronic coronary occlusion: eight-year experience and outcomes by a propensity score ascertainmentMilosz Jaguszewski, Dariusz Ciecwierz, Natasza Gilis-Malinowska, et al.
European Heart Journal|September 17, 2010
Sudden death in hypertrophic cardiomyopathy: old risk factors re-assessed in a new model of maximalized follow-upPawel Petkow Dimitrow, Lidia Chojnowska, Tomasz Rudzinski, et al.
JACC. Heart Failure|July 16, 2014
Exercise capacity and mortality in patients with ischemic left ventricular dysfunction randomized to coronary artery bypass graft surgery or medical therapy: an analysis from the STICH trial (Surgical Treatment for Ischemic Heart Failure)Ralph A H Stewart, Dominika Szalewska, Lilin She, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
European Heart Journal|April 28, 2025
ApoB-containing lipoproteins: count, type, size, and risk of coronary artery diseaseJakub Morze, Giorgio E M Melloni, Clemens Wittenbecher, et al.
Kardiologia Polska|April 22, 2016
[Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement]Barbara Cybulska, Zbigniew Gaciong, Piotr Hoffman, et al.
The Cochrane Database of Systematic Reviews|October 25, 2021
Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysisTakayoshi Kanie, Atsushi Mizuno, Yoshimitsu Takaoka, et al.
The Journal of Invasive Cardiology|November 5, 2013
Major adverse cardiovascular events after drug-eluting stent implantation in patients with single chronic total occlusion: a single-center registryNatasza Gilis-Siek, Marcin Fijalkowski, Milosz Jaguszewski, et al.
Life (Basel, Switzerland)|November 7, 2020
Monitoring the Effects of Hypolipidemic Treatment in Children with Familial Hypercholesterolemia in PolandMatylda Hennig, Agnieszka Brandt-Varma, Anna Wołoszyn-Durkiewicz, et al.
Journal of Clinical Lipidology|June 4, 2013
Management of familial heterozygous hypercholesterolemia: Position Paper of the Polish Lipid Expert ForumAndrzej Rynkiewicz, Barbara Cybulska, Maciej Banach, et al.
Cardiovascular Diabetology|November 23, 2018
Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier?Guntram Schernthaner, Chaim Lotan, Elina Baltadzhieva-Trendafilova, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|January 21, 2015
Successful versus unsuccessful antegrade recanalization of single chronic coronary occlusion: eight-year experience and outcomes by a propensity score ascertainmentMilosz Jaguszewski, Dariusz Ciecwierz, Natasza Gilis-Malinowska, et al.
European Heart Journal|September 17, 2010
Sudden death in hypertrophic cardiomyopathy: old risk factors re-assessed in a new model of maximalized follow-upPawel Petkow Dimitrow, Lidia Chojnowska, Tomasz Rudzinski, et al.
JACC. Heart Failure|July 16, 2014
Exercise capacity and mortality in patients with ischemic left ventricular dysfunction randomized to coronary artery bypass graft surgery or medical therapy: an analysis from the STICH trial (Surgical Treatment for Ischemic Heart Failure)Ralph A H Stewart, Dominika Szalewska, Lilin She, et al.
Pageof 9